Hsa-miR-29c-5p在卵巢透明细胞癌中的表达及对细胞增殖迁移的影响

Abstract
Figure/Table
References (23)
Related Citation (15)

Download: PDF (843 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the expression of Hsa-miR-29c-5p in ovarian clear cell carcinoma and its effect on cell proliferation and migration. Methods The expression of Hsa-miR-29c-5p in human ovarian clear cell carcinoma cell lines (ES-2) and human normal ovarian epithelial cell lines (IOSE80) was detected by qRT-PCR. ES-2 was divided into transfection group and control group. The transfection group was transfected with Hsa-miR-29c-5p mimics by siRNA transfection, and the control group was transfected with miR-NC. Fluorescence microscopy and qRT-PCR were used to detect the expression of Hsa-miR-29c-5p in the two groups, CCK-8 method was used to detect the proliferation of the two groups, and scratch test was used to detect the migration ability of the two groups. Results The expression of Hsa-miR-29c-5p in ES-2 was significantly lower than that in IOSE80, and the difference was statistically significant (P ＜ 0.05). Fluorescence microscopy showed uniform bright red fluorescence in two groups, and qRT-PCR showed that the expression of Hsa-miR-29c-5p in the transfection group was higher than that in the control group, with statistical significance (P ＜ 0.05). There was no significant difference in proliferation ability between the two groups at 24, 48 h after transfection (P ＞ 0.05). At 72, 96 h after transfection, the proliferation ability of transfection group was lower than that of control group at the same time, and the difference was highly statistically significant (P ＜ 0.01). The results of scratch test showed that the lateral migration of ES-2 was highly inhibited after transfection of Hsa -miR-29c-5p for 48 h. The scratch area calculation showed that the scratch area of the transfection group was larger than that of the control group 48 h after transfection, and the difference was highly statistically significant (P ＜ 0.01). Conclusion Comparing with IOSE80, the expression of Hsa-miR-29c-5p in ES-2 is down-regulated. Overexpression of Hsa-miR-29c-5p inhibits ES-2 cell proliferation and migration.

Key words： Ovarian clear cell carcinoma Hsa-miR-29c-5p Proliferation Migration

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DENG Mengqi ZHANG Yanqin CHANG Xiangyu WU Di XU Chunyu MIAO Jinwei

Cite this article:

DENG Mengqi ZHANG Yanqin CHANG Xiangyu WU Di XU Chunyu MIAO Jinwei. Expression of Hsa-miR-29c-5p in ovarian clear cell carcinoma and its effect of cell proliferation and migration[J]. 中国医药导报, 2021, 18(11): 25-28.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I11/25

[1] Li D，Zhang J，Li J. Role of miRNA sponges in hepatocellular carcinoma [J]. Clin Chim Acta，2020，500：10-19.
[2] Wang JY，Yang Y，Ma Y，et al. Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma [J]. Biomed Pharmacother，2020，121：109627.
[3] Bofill-De Ros X，Yang A，Gu S. IsomiRs：Expanding the miRNA repression toolbox beyond the seed [J]. Biochim Biophys Acta Gene Regul Mech，2020，1863（4）：194373.
[4] Kwon JJ，Factora TD，Dey S，et al. A Systematic Review of miR-29 in Cancer [J]. Mol Ther Oncolytics，2018，12：173-194.
[5] Alizadeh M，Safarzadeh A，Beyranvand F，et al. The potential role of miR-29 in health and cancer diagnosis，prognosis，and therapy [J]. J Cell Physiol，2019，234（11）：19280-19297.
[6] 张姣.Hsa-miR-29c在食管鳞状细胞癌中表达的临床意义及功能研究[D].南京：东南大学，2015.
[7] 束翌俊.Hsa-miR-29c调控人胆囊癌细胞增殖转移的机制研究[D].上海：上海交通大学，2015.
[8] 唐浩莎，王肖，刘艳，等.基于单中心的卵巢子宫内膜样囊肿起源的卵巢透明细胞癌临床特征及预后分析[J]．中国临床医学，2018，25（2）：203-209.
[9] Oda K，Hamanishi J，Matsuo K，et al. Genomics to immunotherapy of ovarian clear cell carcinoma：Unique opportunities for management [J]. Gynecol Oncol，2018，151（2）：381-389.
[10] Improta G，Pettinato A，H?覬gdall E，et al. Ovarian Clear Cell Carcinoma：From Morphology to Molecular Biology [J]. Appl Immunohistochem Mol Morphol，2019，27（9）：631-636.
[11] Schwartz DR，Kardia SL，et al. Gene expression in ovarian cancer reflects both morphology and biological behavior，distinguishing clear cell from other poor-prognosis ovarian carcinomas [J]. Cancer Res，2002，62（16）：4722-4729.
[12] Jenison EL，Montag AG，et al. Clear cell adenocarcinoma of the ovary：a clinical analysis and comparison with serous carcinoma [J]. Gynecol，1989，32（1）：65-71.
[13] Sugiyama T，Kamura T，Kigawa J，et al. Clinical characteristics of clear cell carcinoma of the ovary：a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy [J]. Cancer，2000，88（11）：2584-2589.
[14] Behbakht K，Randall TC，et al. Clinical characteristics of clear cell carcinoma of the ovary [J]. Gynecol Oncol，1998， 70（2）：255-258.
[15] Esquela-Kerscher A，Slack FJ. Oncomirs-microRNAs with a role in cancer [J]. Nat Rev Cancer，2006，6（4）：259-269.
[16] Wong NW，Chen Y，Chen S，et al. OncomiR：an online resource for exploring pan-cancer microRNA dysregulation [J]. Bioinformatics，2018，34（4）：713-715.
[17] Burbury K， MacManus MP. The coagulome and the oncomir：impact of cancer-associated haemostatic dysregulation on the risk of metastasis [J]. Clin Exp Metastasis，2018，35（4）：237-246.
[18] Fang T，Lv H，Lv G，et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer [J]. Nat Commun，2018，9（1）：191.
[19] Ding G，Zhou L，Qian Y，et al. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p [J]. Oncotarget，2015， 6（30）：29877-29888.
[20] Di Leva G，Garofalo M，Croce CM. MicroRNAs in cancer [J]. An-nual Review of Pathology，2014，9（2）：287-314.
[21] Correia de Sousa M，Gjorgjieva M，Dolicka D，et al. Deciphering miRNAs’Action through miRNA Editing [J]. Int J Mol Sci，2019，20（24）：6249.
[22] Shu YJ，Bao RF，Jiang L，et al. MicroRNA-29c-5p suppresses gallbladder carcinoma progression by directly targeting CPEB4 and inhibiting the MAPK pathway [J]. Cell Death Differ，2017，24（3）：445-457.
[23] 张国楠.卵巢透明细胞癌的治疗策略与展望[J].中国实用妇科与产科杂志，2021，37（2）：193-197.